Berendes Elmar, Schmidt Christoph, Van Aken Hugo, Hartlage Maike Grosse, Rothenburger Markus, Wirtz Stefan, Scheld Hans Heinrich, Brodner Gerhard, Walter Michael
Klinik und Poliklinik für *Anästhesiologie und Operative Intensivmedizin and †Herz-, Thorax- und Gefäβchirurgie, University of Münster, Münster, Germany; and ‡Department of Biochemistry, Southwestern Medical Center at Dallas, Dallas, Texas.
Anesth Analg. 2004 Jan;98(1):11-19. doi: 10.1213/01.ANE.0000093249.35075.F1.
This study was performed to determine the secretion pattern and prognostic value of A-type (ANP) and B-type (BNP) natriuretic peptide in patients undergoing cardiac surgical procedures. We measured ANP and BNP in patients undergoing coronary artery bypass grafting (CABG) with (n = 28) or without (n = 32) ventricular dysfunction and in patients undergoing mitral (n = 21) or aortic (n = 24) valve replacement, respectively. Postoperative mortality was recorded up to 730 days after operation. ANP, but not BNP, concentrations were closely associated with volume reloading of the heart after aortic cross-clamp in all patients. The secretion pattern of BNP during surgery was much less uniform. BNP, but not ANP, concentrations correlated with aortic cross-clamp time (r(2) = 0.32; P = 0.006) and postoperative troponin I concentrations (r(2) = 0.22; P = 0.0009) in bypass patients, and preoperative BNP increases were associated with a more frequent postoperative (2-yr) mortality in these patients. Markedly increased preoperative BNP concentrations in mitral (3-fold) and aortic (14-fold) valve disease patients did not further increase during cardiopulmonary surgery. The data suggest that ANP is primarily influenced by intravascular volume reloading of the heart after cross-clamp, whereas the secretion of BNP is related to other factors, such as duration of ischemia and long-term left ventricular pressure and/or excessive intravascular volume. BNP, but not ANP, was shown to be a mortality risk predictor in patients undergoing CABG.
A-type natriuretic peptide is primarily influenced by volume reloading of the heart after cross-clamp, whereas the secretion of B-type natriuretic peptide (BNP) is related to the duration of ischemia and long-term left ventricular pressure and/or volume overload. Preoperative BNP, but not postoperative BNP, concentrations predict long-term outcome after coronary artery bypass grafting.
本研究旨在确定接受心脏外科手术患者中 A 型(ANP)和 B 型(BNP)利钠肽的分泌模式及预后价值。我们分别测量了接受冠状动脉旁路移植术(CABG)且伴有(n = 28)或不伴有(n = 32)心室功能障碍的患者以及接受二尖瓣(n = 21)或主动脉瓣(n = 24)置换术患者的 ANP 和 BNP。记录术后长达 730 天的死亡率。在所有患者中,ANP 浓度而非 BNP 浓度与主动脉阻断后心脏的容量再负荷密切相关。手术期间 BNP 的分泌模式不太一致。在搭桥患者中,BNP 浓度而非 ANP 浓度与主动脉阻断时间(r² = 0.32;P = 0.006)和术后肌钙蛋白 I 浓度(r² = 0.22;P = 0.0009)相关,且这些患者术前 BNP 升高与术后(2 年)更频繁的死亡率相关。二尖瓣(3 倍)和主动脉瓣(14 倍)疾病患者术前 BNP 浓度显著升高,在心肺手术期间未进一步增加。数据表明,ANP 主要受主动脉阻断后心脏血管内容量再负荷的影响,而 BNP 的分泌与其他因素有关,如缺血持续时间、长期左心室压力和/或血管内容量过多。在接受 CABG 的患者中,BNP 而非 ANP 被证明是死亡风险预测指标。
A 型利钠肽主要受主动脉阻断后心脏容量再负荷的影响,而 B 型利钠肽(BNP)的分泌与缺血持续时间、长期左心室压力和/或容量超负荷有关。术前 BNP 浓度而非术后 BNP 浓度可预测冠状动脉旁路移植术后的长期预后。